3 BPC-157 has been effective in treating various skin injuries, including incisional/excisional wounds, deep burns, and diabetic ulcers
Most users who escalated doses in the first one to two weeks were doing so before sufficient time had passed for structural recovery to manifest
Furthermore, we systematically revealed the molecular mechanism of chronic hypoxia-induced -syn pathology and neuronal injury
What BPC-157 Is and Why It Comes as a Powder BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a protective protein found in human gastric juice
Compounded tirzepatide vials come in various sizes and concentrations, and the number of doses you get depends on both
&srotate=0)
Aggressive simultaneous protocol (higher risk) Simultaneous start (both from week 1): Tirzepatide standard titration: Same as conservative: 2.5mg 12.5mg over 16 weeks Cagrilintide standard titration (parallel): Weeks 1-4: 0.6mg weekly Weeks 5-8: 1.2mg weekly Weeks 9-12: 1.8mg weekly Week 13+: 2.4mg weekly Aggressive dosing table: Why this is risky: Compounding side effects from start Very difficult to tolerate High dropout risk Unclear if any additional benefit Both hitting stomach simultaneously Potential maximum weight loss: 20-30% body weight (theoretical) Example: 240 lbs 168-192 lbs (48-72 lbs lost) But tolerability extremely questionable Who might attempt: Exceptional GI tolerance Prior success with GLP-1s without nausea Closely monitored by physician Willing to accept high side effect risk Can afford $1,200-2,400/month Understands experimental nature Lower cagrilintide doses with tirzepatide Moderate approach: Tirzepatide: Standard titration to 10-15mg Cagrilintide: Maximum 1.2-1.8mg (lower than standard 2.4mg) Rationale: Tirzepatide doing heavy lifting already Cagrilintide just adds amylin pathway Don't need maximum cagrilintide dose Better tolerability Significantly lower cost Moderate dosing comparison: Verdict: Lower cagrilintide doses (0.6-1.2mg) might be tolerable but benefit questionable
